Press Release - Oslo, Norway, June 8, 2026: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, and Artera, a leading precision medicine company,
announce launch of a joint research initiative. The collaboration encompasses
Photocure's blue light cystoscopy (BLC[®]) registry in bladder cancer and the
ArteraAI Bladder Test, an AI-powered digital pathology test currently in
development for patients with bladder cancer.

As healthcare systems increasingly embrace precision medicine, the demand for
advanced precision diagnostics in uro-oncology continues to grow. Photocure,
already recognized for its proven leadership in bladder cancer diagnostics where
accuracy is critical, is well positioned to meet this need. This research
initiative with Artera underscores Photocure's commitment to grow an array of
complementary diagnostic solutions to address the evolving needs of patients,
physicians, and the broader healthcare community, towards more personalized,
data-driven care in uro-oncology, enabling better clinical outcomes and
supporting the shift toward precision medicine.

The research collaboration will provide Artera with access to high-quality data
from the Photocure U.S. BLC registry to further validate the ArteraAI Bladder
Test. Together, the companies will utilize real world evidence to help
urologists more effectively identify bladder cancer and manage its treatment.
Unlike many other cancers, there are fewer well-established biomarkers in
bladder cancer, which currently limits clinicians from personalizing treatment
options. The partnership between Photocure and Artera is dedicated to advancing
research that guides smarter treatment decisions and helps patients receive
therapies best suited to their disease.

The objectives of using the BLC registry's long-term clinical practice data are
to develop, evaluate, and optimize the performance of Artera's multimodal AI
(MMAI) histopathology biomarkers in patients with non-muscle invasive bladder
cancer (NMIBC). The joint research aims to validate the prognostic and
predictive capabilities of the ArteraAI Bladder by addressing critical clinical
questions.

"With this collaboration, we are exploring additional ways to enter scientific
collaborations that may utilize Photocure's BLC registry to advance the field of
precision diagnostics. When urologists use BLC, they often perform biopsies and
resection to achieve a more accurate diagnosis and a more complete procedural
outcome. By pairing the BLC captured specimen with the ArteraAI Bladder Test, we
aim to accurately determine the grade and stage of disease while also providing
a readout on whether these patients are optimal candidates for specific follow
-up drug therapy. BLC and Artera's AI-powered biomarkers have the promise to set
patients on the right course of bladder cancer management, streamlining the
decision-making for pathologists and urologists," said Anders Neijber, Chief
Medical Officer of Photocure.

"Artera is excited to be working with Photocure to expand the application of our
MMAI algorithms into other genitourinary cancers. Given the impact we've made to
date in the prostate cancer realm, we hope to make a similar impact in bladder
cancer and deliver personalized prognostic and predictive insights to patients
and physicians," said Andre Esteva, co-founder and CEO of Artera.

"Building on the success of BLC, Photocure is expanding its vision to develop a
complementary suite of precision diagnostic solutions. With established
expertise, relationships and a track record in bladder cancer, we are uniquely
placed to drive progress and set new standards in the future of uro-oncology
precision diagnostics. Today we are seeking to accelerate the advancement of
personalized care in a manner that has not previously been achieved. Along with
Artera, we are truly excited about what we can do for urologists, their staff
and their patients," said Dan Schneider, President and CEO of Photocure.

For more information, please contact:

Photocure:

Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]

Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: [email protected]

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]

Artera:

Media Contact:

Vanessa Donohue
Email: [email protected]

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA, except for Artera.


This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],
614 000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3 ]Sievert KD et al. World J Urol 2009;27:295-300
[4 ]Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

About BLC[®] with Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to https://photocure.com/partners/our-partners for further information on our
commercial partners.
The following safety information is solely included to comply with U.S.
regulatory requirements: Important Risk & Safety Information for
Cysview (https://packageinsert.s3.us-east
-2.amazonaws.com/Cysview+PI+2020.pdf)[®] (hexaminolevulinate
HCl) (https://packageinsert.s3.us-east-2.amazonaws.com/Cysview+PI+2020.pdf)

About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

About Artera
Artera is a global leader in precision medicine, leveraging multimodal
artificial intelligence (MMAI) to personalize cancer care. Artera's MMAI
platform leverages a patient's digitized histopathology images along with the
patient's clinical data to determine cancer aggressiveness and predict therapy
benefit. Artera's flagship product, the ArteraAI Prostate Test, is commercially
available as a laboratory-developed test in the US and internationally through
its distribution partners. The ArteraAI Prostate Test is the first of its kind
to deliver both prognostic and predictive insights for patients with prostate
cancer, empowering clinicians and patients to make more informed treatment
decisions.
stribution partners. The ArteraAI Prostate Test is the first of its kind\
to deliver both prognostic and predictive insights for patients with prostate\
cancer\, empowering clinicians and patients to make more informed treatment\
decisions.\